Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cardiol Therapeutics (TSE:CRDL)
TSX:CRDL
Holding TSE:CRDL?
Track your performance easily
CRDL Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.32 - C$4.26
Previous CloseN/A
Volume34.34K
Average Volume (3M)64.70K
Market Cap
$140.36M
Enterprise ValueC$172.15M
Total Cash (Recent Filing)$2.36M
Total Debt (Recent Filing)$190.04K
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Mar 27, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding81,603,424
10 Day Avg. Volume39,506
30 Day Avg. Volume64,698
Standard Deviation0.22
R-Squared0.02
Alpha0.00163
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.82
Forecast
1Y Price Target
C$12.96Price Target Upside636.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Cardiol Therapeutics News
PremiumCompany Announcements
Cardiol Therapeutics Reports Promising Phase II Results
PremiumCompany Announcements
Cardiol Therapeutics Faces Rising Losses and Falling Assets
PremiumCompany Announcements
Cardiol Therapeutics Expands Trials for Heart Treatment
PremiumCompany Announcements
Cardiol Therapeutics Raises $15.5 Million in Offering
PremiumCompany Announcements
Cardiol Therapeutics Secures $13.5M in Public Offering
Options Prices
Currently, No data available
---
Ownership Overview
5.34% Insiders
0.06% Mutual Funds
5.46% Other Institutional Investors
87.62% Public Companies and Individual Investors
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was C$1.32 and its highest was C$4.26 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is $140.36M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 67 days.
How were Cardiol Therapeutics’s earnings last quarter?
Cardiol Therapeutics released its earnings results on Nov 14, 2024. The company reported -C$0.18 earnings per share for the quarter, missing the consensus estimate of -C$0.127 by -C$0.053.
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 81,603,424 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Cardiol Therapeutics reported an EPS of -C$0.18 in its last earnings report, missing expectations of -C$0.127. Following the earnings report the stock price went down -3.053%.
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in TSE:CRDL
---
Cardiol Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$12.96 (636.44% Upside)
C$12.96 (636.44% Upside)
Blogger Sentiment
Bullish
TSE:CRDL Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $224.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days <0.1%
Last 30 Days <0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.62%
12-Months-Change
Fundamentals
Return on Equity
-158.52%
Trailing 12-Months
Asset Growth
-59.28%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics, Inc. is a biotechnology company, which engages in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for inflammatory diseases. Its products pipelines include heart failure products, glioblastoma multiforme and pharmaceutical cannabidol. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
---
CRDL Stock 12 Month Forecast
Average Price Target
C$12.96
▲(636.44% Upside)
Technical Analysis
Cardiol Therapeutics
―
TG Therapeutics
―
Armata Pharmaceuticals
―
Bioxcel Therapeutics
―
Cyclacel Pharmaceuticals
―
SELLAS Life Sciences Group
―
Best Analysts Covering CRDL
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
+13.24%
reiterated a buy rating 2 months ago
Copying Edward Nash's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of +13.24% per trade.
---